AR117677A1 - Tratamiento tópico del inhibidor de puntos de control inmunitario de la diarrea, colitis o enterocolitis inducida mediante el uso de anticuerpos y fragmentos de este - Google Patents

Tratamiento tópico del inhibidor de puntos de control inmunitario de la diarrea, colitis o enterocolitis inducida mediante el uso de anticuerpos y fragmentos de este

Info

Publication number
AR117677A1
AR117677A1 ARP190103582A ARP190103582A AR117677A1 AR 117677 A1 AR117677 A1 AR 117677A1 AR P190103582 A ARP190103582 A AR P190103582A AR P190103582 A ARP190103582 A AR P190103582A AR 117677 A1 AR117677 A1 AR 117677A1
Authority
AR
Argentina
Prior art keywords
fragments
inhibitor
colitis
antibodies
control points
Prior art date
Application number
ARP190103582A
Other languages
English (en)
Inventor
Cristina Bruno
Roberto Bravo
Ortrud Gerstner
Marijana Nedeljkovic
Johannes Spleiss
Felipe Varum
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of AR117677A1 publication Critical patent/AR117677A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a el uso tópico y terapéutico de las composiciones que contienen moléculas de anticuerpos o fragmentos funcionales o derivados específicos del factor de necrosis tumoral a (TNFa) para el tratamiento o la prevención de efectos secundarios provocados por el inhibidor de puntos de control inmunitario.
ARP190103582A 2018-12-07 2019-12-06 Tratamiento tópico del inhibidor de puntos de control inmunitario de la diarrea, colitis o enterocolitis inducida mediante el uso de anticuerpos y fragmentos de este AR117677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2018/084057 WO2020114616A1 (en) 2018-12-07 2018-12-07 Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Publications (1)

Publication Number Publication Date
AR117677A1 true AR117677A1 (es) 2021-08-25

Family

ID=64901487

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103582A AR117677A1 (es) 2018-12-07 2019-12-06 Tratamiento tópico del inhibidor de puntos de control inmunitario de la diarrea, colitis o enterocolitis inducida mediante el uso de anticuerpos y fragmentos de este

Country Status (22)

Country Link
US (1) US20220119515A1 (es)
EP (1) EP3891178A1 (es)
JP (2) JP2022510175A (es)
KR (1) KR20210102879A (es)
CN (1) CN113166238A (es)
AR (1) AR117677A1 (es)
AU (1) AU2019394744A1 (es)
BR (1) BR112021010516A2 (es)
CA (1) CA3116947A1 (es)
CL (1) CL2021001384A1 (es)
CO (1) CO2021007678A2 (es)
CR (1) CR20210298A (es)
EA (1) EA202191454A1 (es)
GE (1) GEP20247601B (es)
IL (1) IL283354A (es)
JO (1) JOP20210118A1 (es)
MA (1) MA54368A (es)
MX (1) MX2021006396A (es)
PH (1) PH12021551337A1 (es)
SG (1) SG11202105429XA (es)
TW (1) TW202038998A (es)
WO (2) WO2020114616A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113331137B (zh) * 2021-05-24 2023-02-03 山东省药学科学院 一种结肠炎复合免疫佐剂及其应用方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
FI20000780A (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
CA2505326A1 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
EP1838735A2 (en) 2004-12-31 2007-10-03 Genentech, Inc. Polypeptides that bind br3 and uses thereof
BRPI0611765B1 (pt) 2005-06-07 2022-09-27 Esbatech Ag Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica
ES2626610T3 (es) * 2005-08-30 2017-07-25 Intrexon Actobiotics Nv Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal
AU2006311475A1 (en) * 2005-11-08 2007-05-18 Medarex, Inc. TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
SI2152250T1 (sl) 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
JP5856480B2 (ja) 2008-06-25 2016-02-09 エスバテック − ア ノバルティスカンパニー エルエルシー 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化
ES2861592T3 (es) 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
BRPI0915460A2 (pt) 2008-07-10 2015-11-10 Esbatech Alcon Biomed Res Unit métodos e composições para a liberação intensificada de macromoléculas
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
KR101900280B1 (ko) 2010-12-23 2018-11-08 얀센 바이오테크 인코포레이티드 활성 프로테아제-저항성 항체 Fc 돌연변이체
JP7155008B2 (ja) 2016-03-14 2022-10-18 ウニヴァーシテテット イ オスロ 変化されたＦｃＲｎを有する改変された免疫グロブリン
CA3011502A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnf.alpha.-antibodies and functional fragments thereof
BR112018017276A2 (pt) 2016-03-17 2019-02-05 Numab Innovation Ag anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos
EP3219727B1 (en) 2016-03-17 2020-12-16 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
PL3219726T3 (pl) 2016-03-17 2021-07-19 Tillotts Pharma Ag Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
EP3409688A1 (en) * 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
ES2978167T3 (es) 2017-09-19 2024-09-06 Tillotts Pharma Ag Variantes de anticuerpos
EP3456738B1 (en) 2017-09-19 2024-07-17 Tillotts Pharma Ag Antibody variants
PT3456736T (pt) 2017-09-19 2021-05-28 Tillotts Pharma Ag Variantes de anticorpos

Also Published As

Publication number Publication date
MA54368A (fr) 2021-10-13
CO2021007678A2 (es) 2021-07-30
TW202038998A (zh) 2020-11-01
EP3891178A1 (en) 2021-10-13
CR20210298A (es) 2021-07-30
CA3116947A1 (en) 2020-06-11
WO2020114616A1 (en) 2020-06-11
CL2021001384A1 (es) 2021-11-12
WO2020115277A1 (en) 2020-06-11
AU2019394744A1 (en) 2021-05-20
JP2022510175A (ja) 2022-01-26
MX2021006396A (es) 2021-07-15
CN113166238A (zh) 2021-07-23
KR20210102879A (ko) 2021-08-20
BR112021010516A2 (pt) 2021-08-31
JOP20210118A1 (ar) 2023-01-30
IL283354A (en) 2021-07-29
PH12021551337A1 (en) 2021-11-29
US20220119515A1 (en) 2022-04-21
JP2024109837A (ja) 2024-08-14
SG11202105429XA (en) 2021-06-29
EA202191454A1 (ru) 2021-10-12
GEP20247601B (en) 2024-02-26

Similar Documents

Publication Publication Date Title
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2019000508A1 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados.
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
CL2016000400A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
BR112016014952A2 (pt) Inibição direcionada de tgfbeta
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
BR112018069927A2 (pt) terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação
MX2024006614A (es) Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer.
CO7000770A2 (es) Terapia combinada para el tratamiento del cáncer de ovario
BR112018008900A8 (pt) composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
CL2020000812A1 (es) Semaglutida en la terapia médica.
AR108890A1 (es) Inhibidores de la entrada del cmvh
AR117677A1 (es) Tratamiento tópico del inhibidor de puntos de control inmunitario de la diarrea, colitis o enterocolitis inducida mediante el uso de anticuerpos y fragmentos de este
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica